Comment on 'The mechanism of ncRNA in trastuzumab resistance in HER2-positive tumors'.

IF 3.5 4区医学 Q2 ONCOLOGY

Medical Oncology Pub Date : 2025-09-24 DOI:10.1007/s12032-025-03064-x

Kadri Altundag

引用次数: 0

查看原文本刊更多论文

关于“her2阳性肿瘤中ncRNA在曲妥珠单抗耐药中的作用机制”的评论。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Medical Oncology 医学-肿瘤学

CiteScore

4.20

自引率

2.90%

发文量

259

审稿时长

1.4 months

期刊介绍： Medical Oncology (MO) communicates the results of clinical and experimental research in oncology and hematology, particularly experimental therapeutics within the fields of immunotherapy and chemotherapy. It also provides state-of-the-art reviews on clinical and experimental therapies. Topics covered include immunobiology, pathogenesis, and treatment of malignant tumors.